このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy

2026年6月23日 更新者:Nutraland USA, Inc.

The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.

The main questions it aims to answer are:

  • Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?
  • Does Miricell support brain health, metabolic health, and visible signs of aging?
  • What medical problems, if any, do participants experience while taking Miricell?

Researchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.

Participants will:

  • Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.
  • Visit the research clinic four times over the course of the study for checkups and tests.
  • Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.

調査の概要

詳細な説明

This randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluates the physiological impacts of a standardized spermidine ingredient (Miricell®) over a 12-week intervention period.

Participants are randomized in a 1:1 ratio into one of two parallel groups. To ensure rigorous double-blind conditions, investigators, research site staff, and participants remain masked to group allocations throughout the duration of the trial. Investigational products are supplied in identical-looking, opaque capsules packaged in coded bottles to prevent accidental unblinding. The randomization schedule is maintained securely and will only be broken in the event of a medical emergency requiring immediate knowledge of the treatment assignment.

To minimize confounding variables related to endogenous autophagy activation and variable background polyamine intake, strict lifestyle compliance measures are enforced across both groups:

  • Participants receive detailed instructions to avoid altering their baseline intake of polyamine-rich foods (such as aged cheeses, fermented soy, and specific grains/mushrooms) to ensure nutritional stability.
  • Dietary tracking is deployed at multiple intervals to longitudinally verify caloric and macronutrient consistency throughout the study period.
  • Prior to scheduled laboratory evaluations, participants must replicate their individual 24-hour baseline diet, abstain from alcohol and heavy physical exertion for 24 hours, avoid caffeine for 12 hours, and maintain a strict 10-hour overnight fast.

Participant safety is continuously monitored by the investigative medical staff. All local or systemic adverse events are systematically evaluated and categorized by clinical severity. Internal data monitoring and quality assurance reviews are performed regularly by designated site staff to guarantee protocol adherence and regulatory compliance. Backup blood samples are kept from each visit to protect against any laboratory or processing errors.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Ohio
      • Canfield、Ohio、アメリカ、44406
        • 募集
        • The Center for Applied Health Sciences
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

説明

INCLUSION CRITERIA:

  • Provide voluntary signed and dated informed consent.
  • Be in fair health as determined by medical history and routine blood chemistries.
  • Age between the ages of 40 and 70 (inclusive).
  • Body weight of at least 110 pounds.
  • Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • Normal seated, resting heart rate (<90 per minute).
  • Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.
  • Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Participant is willing and able to comply with the study protocol.
  • If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.
  • Able to provide an adequate blood draw.

EXCLUSION CRITERIA:

  • Use of probiotics, postbiotics or antibiotics within the past month.
  • A history of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal disease.
  • The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug/alcohol abuse or dependence.
  • History of diabetes (any form) or any endocrine disorder.
  • Fasting blood sugar of > 125 mg/dL.
  • Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).
  • History of hyperparathyroidism or an untreated thyroid disease.
  • History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of gout or fibromyalgia.
  • Any female who is pregnant, trying to become pregnant, is less than/or equal to 120 days postpartum, or any current women who are nursing.
  • Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.
  • Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.
  • Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Miricell™
Participants assigned to this arm will receive one capsule of the active branded spermidine supplement (Miricell) daily for a total duration of 12 weeks.
Branded spermidine ingredient (Miricell® Rice Germ Extract) administered orally at a dose of 3.3 mg/day. Provided as a single opaque capsule to be ingested daily with water in the morning with a meal.
プラセボコンパレーター:Placebo
Participants assigned to this arm will receive one look-alike placebo capsule daily for a total duration of 12 weeks.
Placebo capsule (microcrystalline cellulose) packaged in an identical-looking, opaque capsule to be ingested daily with water in the morning with a meal.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Serum Beclin-1 Concentration
時間枠:Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum Beclin-1 levels to assess autophagy activation.
Baseline (Week 0), Week 6, and Week 12
Serum ULK1 Concentration
時間枠:Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum ULK-1 levels to assess autophagy activation.
Baseline (Week 0), Week 6, and Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Brain-Derived Neurotrophic Factor (BDNF) Concentration
時間枠:Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum BDNF levels to evaluate indices of neuroprotection.
Baseline (Week 0), Week 6, and Week 12
High-Sensitivity C-Reactive Protein (hs-CRP) Concentration
時間枠:Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in hs-CRP levels to evaluate systemic inflammatory status and cardio-metabolic health.
Baseline (Week 0), Week 6, and Week 12
Fasting Insulin Concentration
時間枠:Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in fasting insulin levels to calculate changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Baseline (Week 0), Week 6, and Week 12
Cognitive Function Score via CNS Vital Signs
時間枠:Baseline (Week 0), Week 6, and Week 12
Evaluation of neurocognitive performance domains using the computerized CNS Vital Signs testing platform.
Baseline (Week 0), Week 6, and Week 12
Patient-Reported Outcomes Measurement Information System - Cognitive Function (PROMIS-CF) Score
時間枠:Baseline (Week 0), Week 6, and Week 12
Participant-reported evaluation of cognitive capabilities utilizing the standardized PROMIS-CF Short Form 8a questionnaire
Baseline (Week 0), Week 6, and Week 12
Patient-Reported Outcomes Measurement Information System - Cognitive Function - Abilities (PROMIS-CF-A) Score
時間枠:Baseline (Week 0), Week 6, and Week 12
Participant-reported evaluation of cognitive abilities utilizing the standardized PROMIS-CF-A Short Form 8a questionnaire.
Baseline (Week 0), Week 6, and Week 12
Lipid Panel Metrics
時間枠:Baseline (Week 0), Week 6, and Week 12
Standard clinical panel measuring fasting serum cholesterol fractions (Total, LDL, HDL) and triglycerides to evaluate lipid homeostasis.
Baseline (Week 0), Week 6, and Week 12

その他の成果指標

結果測定
メジャーの説明
時間枠
Phenotypic Age (PhenoAge)
時間枠:Baseline (Week 0), Week 6, and Week 12
An assessment of biological age calculated using a validated multi-variable algorithm incorporating chronological age alongside specific clinical biomarkers from the complete blood count (CBC), comprehensive metabolic panel (CMP), and hs-CRP.
Baseline (Week 0), Week 6, and Week 12
Subjective Hair and Nail Health Likert Scores
時間枠:Baseline (Week 0), Week 6, and Week 12
Evaluation of subjective visible signs of aging assessed via custom Likert-style questionnaires rating hair and nail appearance/quality.
Baseline (Week 0), Week 6, and Week 12
Quality of Life Score (SF-36)
時間枠:Baseline (Week 0), Week 6, and Week 12
Evaluation of general health-related quality of life metrics using the standardized 36-Item Short Form Survey (SF-36).
Baseline (Week 0), Week 6, and Week 12
Body Composition via Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline (Week 0), Week 6, and Week 12
Assessment of shifts in fat mass and fat-free mass using an InBody 570 analyzer to track physiological changes over time.
Baseline (Week 0), Week 6, and Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月9日

一次修了 (推定)

2026年9月1日

研究の完了 (推定)

2026年9月1日

試験登録日

最初に提出

2026年6月23日

QC基準を満たした最初の提出物

2026年6月23日

最初の投稿 (実際)

2026年6月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月30日

QC基準を満たした最後の更新が送信されました

2026年6月23日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する